 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
19 News |  |
- | danegaptide (ZP1609) / Zealand Pharma
Journal, MRI: Scar border zone mass and presence of border zone channels assessed with cardiac magnetic resonance imaging are associated with ventricular arrhythmia in patients with ST-segment elevation myocardial infarction. (Pubmed Central) - Dec 29, 2022
P=N/A, P2
Scar characterization with CMR indicates that a combination of ≥17.2 g BZ mass and the presence of BZ channels had the strongest association with subsequent VA in STEMI patients.
- | danegaptide (ZP1609) / Zealand Pharma, Myrbetriq (mirabegron) / Astellas
Journal: Activating Connexin43 gap junctions primes adipose tissue for therapeutic intervention. (Pubmed Central) - Jul 24, 2022
In light of these findings, we propose a model in which connecting adipocytes via Cx43 gap junction channels primes adipose tissue to pharmacological agents designed to engage it. Thus, Cx43 gap junction activators hold great potential for combination with additional agents targeting adipose tissue.
- | isoflurane / Generic mfg.
Preclinical, Journal: Connexin 43 gap junction-mediated astrocytic network reconstruction attenuates isoflurane-induced cognitive dysfunction in mice. (Pubmed Central) - Apr 8, 2022
Thus, Cx43 gap junction activators hold great potential for combination with additional agents targeting adipose tissue. Our results reveal a novel mechanism of the GJ-Cx43-mediated astrocytic network involved in isoflurane-induced neuroinflammation and cognitive impairments, which provides new mechanistic insight into the pathogenesis of POCD and identifies potential targets for its treatment.
- | danegaptide (ZP1609) / Zealand Pharma
Preclinical, Journal: Gap-134, a Connexin43 activator, prevents age-related development of ventricular fibrosis in Scn5a mice. (Pubmed Central) - Jul 8, 2021
Chronic administration of a potent and selective gap junction modifier, Gap-134 (danegaptide), between 45 and 60 weeks, increased Cx43 expression and phosphorylation on serine 368 and prevented Cx43 delocalization...In conclusion, the present study demonstrates that the age-dependent decrease of Cx43 expression is involved in the ventricular fibrotic process occurring in Scn5a mice. Finally, our study suggests that gap junction modifier, such as Gap-134, could be an effective anti-fibrotic agent in the context of age-dependent fibrosis in progressive cardiac conduction disease.
- | danegaptide (ZP1609) / Zealand Pharma
Journal: Danegaptide Prevents TGFβ1-Induced Damage in Human Proximal Tubule Epithelial Cells of the Kidney. (Pubmed Central) - Apr 23, 2021
Furthermore, danegaptide inhibited TGFβ1-induced changes in the expression and secretion of key adipokines, cytokines, chemokines, growth factors and interleukins. The data suggest that as a gap junction modulator and hemichannel blocker, danegaptide has potential in the future treatment of CKD.
- | danegaptide (ZP1609) / Zealand Pharma
Preclinical, Journal: Danegaptide Enhances Astrocyte Gap Junctional Coupling and Reduces Ischemic Reperfusion Brain Injury in Mice. (Pubmed Central) - Mar 23, 2021
Furthermore, administration of danegaptide in a novel mouse brain ischemia/reperfusion model showed significant decrease in infarct volume. Taken together, this study provides evidence for the therapeutic potential of danegaptide in ischemia/reperfusion stroke.
- | danegaptide (ZP1609) / Zealand Pharma
Biomarker, Preclinical, Journal: A human in vitro platform for the evaluation of pharmacology strategies in cardiac ischemia. (Pubmed Central) - Aug 22, 2019
ZP1609 significantly improved the drastic drop in conduction velocity and enabled a greater recovery. This model represents a new preclinical platform for studying cardiac ischemia with human cells, which does not rely on biomarker analysis and has the potential for screening novel cardioprotective drugs with readouts that are closer to the measured clinical parameters.
- |||| danegaptide (ZP1609) / Zealand Pharma
Trial completion: Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction (clinicaltrials.gov) - Jan 16, 2016
P2, N=591, Completed, Sponsor: Zealand Pharma
This model represents a new preclinical platform for studying cardiac ischemia with human cells, which does not rely on biomarker analysis and has the potential for screening novel cardioprotective drugs with readouts that are closer to the measured clinical parameters. Recruiting --> Completed
- danegaptide (ZP1609) / Zealand Pharma
Trial primary completion date: Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction (clinicaltrials.gov) - Jul 6, 2015
P2, N=600, Recruiting, Sponsor: Zealand Pharma
Recruiting --> Completed Trial primary completion date: May 2015 --> Dec 2015
- |||| danegaptide (ZP1609) / Zealand Pharma
Enrollment open: Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction (clinicaltrials.gov) - Nov 26, 2013
P2, N=600, Recruiting, Sponsor: Zealand Pharma
Trial primary completion date: May 2015 --> Dec 2015 Not yet recruiting --> Recruiting
- ||||| danegaptide (ZP1609) / Zealand Pharma
New P2 trial: Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction (clinicaltrials.gov) - Nov 5, 2013
P2, N=600, Recruiting, Sponsor: Zealand Pharma